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Abstract: Interaction of the antipsychotic drug risperidone with hydroxypropyl-beta-cyclodextrin (HPBCD) in solution 
and in the solid state was studied with the aim of overcoming the limitations associated with nasal administration of low 
solubility drugs. Risperidone solubility studies revealed inclusion complex formation with a 1:1 stoichiometry. Low con-
centrations (0.1 w/v %) of hydroxypropylmethyl cellulose (HPMC) and carbomer affected risperidone solubility in water. 
No formation of a ternary complex was detected. The solid inclusion complex was prepared by spray drying and was 
characterised by thermal (DSC) and spectral (FTIR) analyses. Risperidone and the inclusion complex were loaded into 
microparticles by spray drying using HPMC, carbomer and HPMC/carbomer interpolymer complex (IPC) as mucoadhe-
sive components. The microparticles were characterised with respect to drug loading, particle size distribution, thermal 
analysis, and zeta potential measurements. Mucoadhesive properties of the microparticles were studied by measuring the 
work of adhesion. Carbomer and IPC based microparticles revealed superior mucoadhesive microparticles compared to 
HPMC based microparticles. Drug incorporation into microparticles reduced their mucoadhesive properties, while incor-
poration of the cyclodextrin complex caused no additional reduction in mucoadhesion. The in vitro dissolution studies 
showed that formation of the inclusion complex significantly increased the risperidone dissolution rate from the micropar-
ticles, thus providing sustained drug release. 
Keywords: Risperidone, hydroxypropyl-beta-cyclodextrin, nasal administration, mucoadhesive microparticles, hydroxypro-
pylmethyl cellulose, carbomer, interpolymer complex. 
1. INTRODUCTION 
 Nasal administration for systemic drug delivery has been 
extensively investigated, and many formulations have been 
marketed [1]. The nasal cavity offers a large, highly vascu-
larised subepithelial layer for efficient drug absorption into 
the systemic circulation, allowing fast onset of drug pharma-
cological effect and avoidance of liver first pass metabolism. 
Numerous studies in animal models and critical evaluation of 
clinical studies have indicated the possibility of direct nose 
to brain drug delivery via the olfactory region of the nasal 
cavity [2]. Nasal administration of small lipophilic molecules 
such as dihydroergotamine, cocaine, lidocaine, and cefalexin 
has resulted in very fast drug appearance in cerebrospinal 
fluid and in the brain, with the same or higher drug concen-
trations compared to intravenous application [2, 3]. Easy 
accessibility of the nasal route facilitates self-medication, 
thereby improving patient compliance compared to par-
enteral routes. Hence, nasal drug application could be a suit-
able alternative to oral application of psychoactive drugs 
such as risperidone. 
 However, nasal drug delivery has certain limitations due 
to the mucociliary clearance of the applied drug formulation 
from the site of deposition, resulting in a short residence 
time for absorption. The use of bioadhesive drug delivery 
systems increases the residence time of formulations in the 
nasal cavity, thus allowing for longer absorption [1]. By  
 
 
*Address correspondence to either author at the Faculty of Pharmacy and 
Biochemistry, University of Zagreb, A. Kovacica 1, 10 000 Zagreb, Croatia; 
Tel: +3851-4612-608; Fax: +3851-4612-691; E-mail: mjug@pharma.hr or 
mira-becirevic@yahoo.com 
using mucoadhesive drug delivery systems, it is possible to 
achieve a more intimate contact with the nasal mucosa, 
which results in a higher concentration gradient of the drug 
and subsequent increased absorption. Mucoadhesive mi-
croparticles are among the most studied nasal drug delivery 
systems [4]. Polymers used in the formulation of mucoadhe-
sive microparticles are usually acrylic acid derivates (car-
bomers), different cellulose esters and chitosan [1,4]. Poly-
mers such as carbomers and chitosan may act as drug ab-
sorption enhancers since they trigger paracellular drug trans-
port [5]. 
 Incorporation of poorly water-soluble drugs, such as 
risperidone, into mucoadhesive microparticles may result in 
incomplete drug delivery because of the limited drug solubil-
ity and dissolution rate within the matrix. This problem can 
be overcome by the use of drug carrier systems such as drug-
cyclodextrin complexes. Mucoadhesive microparticles con-
taining cyclodextrins can provide controlled and complete in 
vitro drug release. Cyclodextrins have been demonstrated to 
be safe nasal absorption enhancers of different drugs, includ-
ing macromolecular and polypeptide drugs [6]. Histological 
and cell-culture based studies [7] have shown that cyclodex-
trins do not induce mucosal damage and have no significant 
influence on the nasal ciliary movement [8]. Further, clinical 
data [6] have shown no significant adverse effects, indicating 
that cyclodextrins are effective and safe excipients for nasal 
drug delivery. 
 Therefore, the aim of the present work was to study the 
complexation of risperidone with hydroxypropyl- -
cyclodextrin, and to develop cyclodextrin based mucoadhe-
sive microparticles for risperidone nasal delivery. 
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2. MATERIALS AND METHODS 
2.1. Materials 
 Risperidone was kindly donated by Pliva, a member of the 
Barr Group (Zagreb, Croatia). Hydroxypropyl- -cyclodextrin 
(HPBCD) with the average substitution degree per anhydro-
glucose unit of 0.9 was used as received (Wacker Chemie 
GmbH, Munich, Germany). Hydroxypropylmethyl cellulose 
(HPMC, Metolose
®
 90 SH; =4000 mPa s; Shin-Etsu Chemi-
cal. Tokyo, Japan) and carbomer (Carbopol
®
 941, =4000 – 
10 000 mPa s; Noveon, Cleveland, USA) were used as muco-
adhesive polymers. All other materials and solvents used were 
of analytical reagent grade. 
2.2. Phase Solubility Studies 
 Phase solubility studies were performed according to the 
method described by Higuchi and Connors [10]. An excess 
amount of risperidone (100 mg) was added to 20 mL of aque-
ous solution containing HPBCD in concentrations ranging 
from 0 to 40 mmol L
-1
 (binary systems). The suspensions were 
vigorously shaken at 25 ± 1
o
C for 3 days until solubility equi-
librium was reached. The samples were filtered through a 0.20 
μm Millipore
®
 membrane filter and drug concentrations in the 
samples were determined spectrophotometrically at a wave-
length of 280 nm (Ultrospec Plus, LKB, Pharmacia, Sweden). 
Preliminary studies showed that the presence of HPBCD did 
not interfere with risperidone absorbance at 280 nm. 
 To establish the effects of HPMC and carbomer on the 
risperidone/HPBCD interaction in solution, the polymer was 
added (0.1% w/v) to the samples (ternary systems). The sus-
pensions were sonicated in an ultrasonic bath for 1 h, at 70ºC, 
and were then allowed to equilibrate at 25 ± 1ºC for 3 days. 
After equilibrium was attained, undissolved drug was removed 
from the samples by centrifugation (3500 rpm, 15 min) and 
the risperidone content was determined by the previously de-
scribed method. 
 The apparent stability constant Ks was calculated from 




    (1) 
where s0 is the solubility of the drug in water (intercept). 
2.3. Preparation of the Solid Complex 
 Risperidone (0.821 g) and an equimolar amount of 
HPBCD (3.0 g) were separately dissolved in 50 mL of 96% 
ethanol and 50 mL of water, respectively. The solutions were 
mixed together and stirred (600 rpm) for 24 h at ambient tem-
perature to obtain complexation equilibrium. The obtained 
solution was subjected to spray drying using a Büchi 190 Mini 
Spray Dryer (Flawil, Switzerland) with a standard 0.5 mm 
nozzle. The drying conditions were as follows: flow rate 0.25 l 
h
-1
, inlet temperature 150
o
C, outlet temperature 100
o
C and air 
flow rate 700 NL h
-1
. 
 The ethanol/water solution of the drug without HPBCD 
was also prepared by the same procedure, and the solid prod-
uct was isolated by spray drying as described above. 
2.4. Preparation of Mucoadhesive Microparticles 
 The microparticles were prepared by spray drying using 
HPMC, carbomer and HPMC/carbomer interpolymer com-
plex (IPC) as mucoadhesive components. IPC was previ-
ously prepared by mixing 1% (w/v) aqueous solutions of 
HPMC and carbomer in a 1:1 volume ratio. The obtained 
solution was stirred uniformly for 1 h and subjected to spray 
drying to prepare IPC in the solid state. The drying condi-
tions were as described in section 2.3. 
 For the preparation of microparticles, the polymer (0.5 g) 
was dissolved in 50 mL of water. Risperidone (0.5 g) or the 
cyclodextrin complex containing the same amount of the 
drug was dissolved in 50 mL of 96% ethanol and mixed with 
the polymer solution. The obtained solution was uniformly 
stirred (600 rpm) at room temperature for 1 h and subjected 
to spray drying under the conditions as described in section 
2.3. Compositions of the microparticles are given in Table 1. 
The mass ratio of risperidone, free or in complex form, and 
mucoadhesive polymer was 1:1 in all the prepared micropar-
ticles. Drug-free (blank) microparticles were prepared ac-
cording to the same procedure, omitting the drug (free or as 
cyclodextrin inclusion complex) from the preparation. 
Table 1. Effect of the Addition of HPMC and Carbomer to 
Aqueous HPBCD Solution on Risperidone Solubil-
ity, Correlation Coefficient of the Solubility Iso-
therm (r
2
) and Apparent Stability Constants of the 
Complexes (Ks) 
 





no polymer - 18.32 0.9952 456.61 ± 12.77 
HPMC 1.94 19.13 0.9870 491.84 ± 11.67 
carbomer 0.96 15.72 0.9855 198.81 ± 6.62 
s0 – risperidone solubility in water. 
sp – risperidone solubility in aqueous solution of the polymer (HPMC or carbomer) 
without HPBCD. 
sCD – risperidone solubility in aqueous solution of the polymer (HPMC or carbomer) 
with 40 mmol L-1 HPBCD. 
 
2.5. Determination of the Drug Content in Solid Products 
 For determination of the drug content in solid products, 
10 mg of the samples was extracted with 96% ethanol under 
sonication in an ultrasonic bath (Branson B1210E-DTH, 
Danbury, USA) until a clear solution was obtained. After 
filtration through a 0.20 μm Millipore
®
 membrane filter, the 
risperidone concentration in the samples was determined 
spectrophotometrically at 280 nm. Drug loading was calcu-
lated as the ratio between the actual and theoretical drug con-
tent in the microparticles, expressed as percentage. 
2.6. Particle Size Determination 
 A microscopical imaging analysis technique was applied 
for the determination of particle size distribution using an 
Olympus BH-2 microscope, equipped with a computer-
controlled image analysis system (Optomax V, Cambridge, 
UK). 
2.7. Differential Scanning Calorimetry (DSC) 
 DSC thermograms of the solid products were recorded on 
a Perkin Elmer DSC 7 (Wellesley, USA). The instrument 
was calibrated with indium and zinc prior to the analysis of 
samples under nitrogen purge. All accurately weighed sam-
ples (2 mg) were placed in sealed aluminium pans, and 
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2.8. FTIR Spectroscopic Studies 
 FTIR spectra of the solid products were recorded on a 
Perkin-Elmer spectrum GX spectrometer. The samples were 
prepared by the potassium bromide disc method (2 mg sam-
ple in 200 mg KBr) and scanned for absorbance in the range 
of 4000– 500 cm
-1
 at 1 cm
1
 resolution. 
2.9. Zeta Potential Measurement 
 The zeta-potential of spray-dried components and pre-
pared microparticles was determined by photon-correlation 
spectroscopy (Zetasizer 3000 HSA, Malvern Instruments, 
UK) in 10 mM NaCl solution (pH 6.7) at 25°C. 
2.10. In Vitro Mucoadhesion Test 
 To evaluate the microparticles mucoadhesive properties, 
a tensile study was performed using bovine nasal mucosa. 
Prepared microparticles (100 mg) as well as drug-free mi-
croparticles (HPMC, carbomer, IPC) were compressed into 
discs of 1 cm diameter by means of a hydraulic press (Glen-
rothes, UK), applying a compression pressure of 160 kPa cm
-
2
. The discs were attached to the stainless steel support con-
nected to a precise balance (Sartorius BP 221S, Goettingen, 
Germany) using cyanoacrylate glue. The bovine nasal mu-
cosa were fixed to the glass dish mounted on the mobile 
support. The mucosal surface was wetted with 0.1 mL of 
simulated nasal fluid (8.77 g NaCl, 2.98 g KCl and 0.59 g 
CaCl2 per 1000 mL of demineralised water; pH 6.4) and 
brought in contact with the sample. The sample and the tis-
sue were left in contact for 5 min, allowing the formation of 
a mucoadhesive bond. The force of detachment was meas-
ured as a function of displacement, by lowering the mobile 
support at a constant rate of 5 mm min
1
 until total separa-
tion of the components was achieved. The work of bioadhe-
sion (W) was calculated as the area under the force/distance 
curve. 
2.11. In Vitro Drug Release Studies 
 The drug release experiments employed a standard Franz 
diffusion cell (PermeGear, USA) with a diffusion area of 
10.18 cm
2
 and an acceptor compartment volume of 16 mL. 
Risperidone, inclusion complex or prepared microparticles 
containing 5 mg of the drug were applied evenly across the 
pre-hydrated semipermeable membrane (Medicell Dialysis 
Tubing, MWCO 600 Da) clamped between the donor and 
acceptor compartments. The membrane was wetted with 0.05 
mL of simulated nasal fluid containing 1% of mucine. After 
the sample was applied, the donor compartment of the Franz-
diffusion cells was closed with Parafilm
®
 “M” sealing film 
(American National Can Company, Chicago, IL, USA) to 
avoid evaporation of the release medium and to allow the 
establishment of constant relative humidity around the sam-
ple. Phosphate buffer (pH 7.4) in the acceptor compartment 
was continuously stirred at 600 rpm using a magnetic stirrer. 
The cells were thermostated at 37ºC. At set time intervals, 
aliquots of the acceptor phase were removed and assayed for 
the drug content. The removed samples were immediately 
replaced with an equal quantity of prewarmed receptor me-
dium. Cumulative corrections were made for previously re-
moved samples. 
 The kinetics of drug release was determined by fitting the 
best fit (r
2
>0.98) of the dissolution data to distinct models: 
zero – order (2) and Higuchi kinetic model (3) defined by the 
following equations: 
Qt = k0t      (2) 
Qt = kH t
1/2
     (3) 
where Qt is the amount of the drug released at time t, k0 and 
kH are zero-order and Higuchi rate constants, respectively. 







100%     (4) 
2.12. Statistical Analysis 
 All values are expressed as mean ± SD of N separate ex-
periments. Data were compared for single comparison by the 
Student's t test and for multiple comparisons by one-way 
ANOVA, followed by the Bonferroni's multiple comparison 
test. Values of p < 0.05 were considered significant. Calcula-
tions were performed using the GraphPad Prism program 
(GraphPad Software, San Diego, CA; www.graphpad.com). 
3. RESULTS 
3.1. Influence of HPMC and Carbomer on Risperidone 
Solubility and Inclusion Complex Formation in Solution 
 The phase solubility studies were intended to investigate 
the influence of HPMC and carbomer on the risperidone 
inclusion complex formation in solution. The obtained phase 
solubility diagrams are shown in Fig. 1. In the binary system, 
risperidone solubility increased linearly as a function of in-
creased HPBCD concentration with the slope < 1, indicating 
formation of the soluble inclusion complex with a 1:1 molar 
stoichiometry. The corresponding stability constant of the 











Fig. (1). Phase solubility diagrams of risperidone and HPBCD in 
water, HPMC and carbomer solution at 25°C (mean ± SD, N = 5). 
 The presence of HPMC and carbomer affected risperi-
done solubility in water. While HPMC increased drug solu-
bility and the stability constant value, the presence of car-
bomer slightly reduced risperidone solubility in water and 
decreased the inclusion stability constant value (Table 1). 
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Addition of polymers to the solution did not influence the 
type of the solubility isotherm; hence, it could be deducted 
that the complex stoichiometry remained the same as in the 
binary system. 
3.2. Solid State Studies of the Risperidone/HPBCD Inclu-
sion Complex 
 Risperidone/HPBCD inclusion complex in solid state 
was prepared in a 1:1 molar ratio by spray drying, based on 
the results of the phase solubility studies. The prepared com-
plex (RHPBCD) was characterised by drug content determina-
tion and particle size distribution. The results were compared 
to the spray-dried drug (R0). Particle size determination indi-
cated a narrow log-normal distribution, with more than 90% 
of particles having spherical diameters ranging from 1-2.5 
μm (Table 2). The inclusion complex formation did not sig-
nificantly affect the mean spherical diameter of the drug mi-
croparticles (p > 0.05). 
 Evidence for the complex formation in the solid state was 
obtained by thermal (DSC) and spectral (FTIR) analyses. 
DSC thermograms of the samples are shown in Fig. 2. 
Thermogram of the crystalline risperidone showed an endo-
thermic fusion peak at 168.5°C ( H=101.6 Jg
-1
). In the 
thermogram of the spray-dried risperidone, the position and 
intensity of the fusion peak did not differ significantly 
(169.6°C; H=101.8 Jg
-1
) compared to that of the crystalline 
drug, indicating that the spray drying procedure did not in-
fluence the drug crystalline state. The HPBCD thermogram 
exhibited a very broad endothermic peak from 45.7 to 140°C 
( H=156.7 Jg
-1
), which could correspond to the loss of water 
molecules from the cyclodextrin cavity. The endothermic 
fusion peak corresponding to drug melting was still evident 
in the thermogram of the risperidone/HPBCD physical mix-
ture (162.2ºC, H=56.82 J/g). In the thermogram of the 
spray-dried inclusion complex, the risperidone fusion peak 
was not present. 
 The FTIR spectra that were obtained are shown in Fig. 3. 
The absorption bands position and intensity in the FTIR 
spectra of spray-dried risperidone were the same as in the 
crystalline drug spectra, indicating the same crystal lattice 
formation and thereby confirming the observations based on 
the DSC results. In the FTIR spectra of the spray-dried in-
clusion complex, the majority of risperidone absorption 
bands disappeared and a shift of amide carbonyl-stretching 
band to lower values could be observed. Also, the intensity 
of amide carbonyl-stretching band in the case of the spray-












Fig. (2). DSC curves of A) crystalline risperidone; B) spray-dried 
risperidone; C) HPBCD; D) equimolar risperidone/HPBCD physi-













Fig. (3). FTIR spectra of A) crystalline risperidone; B) spray-dried 
risperidone; C) HPBCD; and D) spray-dried inclusion complex. 




Mucoadhesive Polymer Drug 
Drug Loading / (%) d( m) 
R0 - risperidone - 2.45±0.76 
RHPBCD - inclusion complex - 2.58±1.23 
MR1 risperidone 84.78 ± 0.79 2.90 ± 1.44 
MR2 
HPMC 
inclusion complex 95.08 ± 0.82 3.20 ± 1.47 
MR3 risperidone 88.34 ± 0.85 2.83 ± 1.28 
MR4 
carbomer 
inclusion complex 102.09 ± 5.40 3.41 ± 1.68 
MR5 risperidone 89.18 ±1.18 2.86 ± 1.86 
MR6 
IPCa 
inclusion complex 104.24 ± 2.40 3.19 ± 1.47 
a HPMC/carbomer interpolymer complex. 
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3.3. Preparation and Characterisation of Mucoadhesive 
Microparticles 
 Risperidone and the inclusion complex were loaded into 
mucoadhesive microparticles by means of spray drying. This 
method is much less dependent on the solubility characteris-
tics of the drug and polymer; it is simple, reproducible and 
easy to scale up. Prepared microparticles were characterised 
by drug content determination, particle size distribution, 
DSC analysis and zeta potential measurement. Also, muco-
adhesive properties of the prepared microparticles were 
evaluated. 
 Drug content determination revealed drug loading into 
microparticles with average spherical diameters approaching 
3.0 μm (Table 2). The presence of the risperidone inclusion 
complex increased the average spherical diameter of the mi-
croparticles compared to cyclodextrin-free microparticles 
(Table 2), but the difference was not statistically significant 
(p > 0.05). The particle size distribution of all prepared mi-
croparticles followed a narrow log-normal distribution, with 
less than 10% of microparticles > 5 μm. The presence of 
larger particles could be attributed to aggregation of mi-
croparticles during the spray-drying procedure. 
 DSC thermograms of the prepared microparticles are 
shown in Fig. 4, and the results are compared to the thermo-
gram of spray-dried risperidone. In all thermograms, a broad 
endothermic peak could be observed in the range of 35 to 
110°C, corresponding to the evaporation of absorbed water. 
In the thermogram of HPMC based microparticles (MR1), an 
endothermic peak corresponding to the drug fusion was ob-
served (159.9°C, H=19.3 J/g), but the peak intensity de-
creased. The peak was shifted to lower temperature com-
pared to spray-dried risperidone (169.6°C, H=110.8 J/g). In 
the thermograms of MR2-MR6 microparticles, the drug fu-













Fig. (4). DSC thermograms of A) spray-dried risperidone; B) the 
prepared microparticles MR1; C) MR2; D) MR3; E) MR4; F) 
MR5; and G) MR6. 
 The results of zeta potential determination are presented 
in Fig. 5. Zeta potentials of the microparticles were com-
pared to the zeta potential of spray-dried risperidone (R0) and 
drug-free microparticles (HPMC, carbomer and IPC, respec-
tively). Zeta potential of drug-free HPMC microparticles was  
 
close to zero due to the non-ionic nature of the polymer. The 
presence of charged carboxyl groups on the particle surface 
gave rise to negative zeta potential values of drug-free car-
bomer microparticles. In the case of drug-free IPC micropar-
ticles, the zeta potential was lower compared to carbomer 




































Fig. (5). Zeta potential values of spray-dried components (drug, 
HPMC, carbomer and IPC) and prepared microparticles. 
 Zeta potential of spray-dried risperidone (R0) was posi-
tive due to partial drug ionisation under the experimental  
 




























Fig. (6). In vitro mucoadhesion of the polymers and prepared mi-
croparticles expressed as the work of adhesion (W; mean ± S.D.; 
n=5). 
conditions. In the case of drug-loaded microparticles based 
on HPMC (MR1 and MR2), the zeta potential value was 
similar to drug-free microparticles based on the same poly-
mer, indicating that the polymer was the dominant compo-
nent on the surface of microparticles (Fig. 5). Negative zeta 
potential values of drug-free and drug-loaded microparticles 
based on carbomer (MR3 and MR4) and IPC (MR5 and 
MR6) pointed to the same conclusion. Zeta potential of car-
bomer based drug loaded microparticles was somewhat 
lower compared to the zeta potential of drug-free carbomer 
microparticles. Drug loading did not significantly affect the 
zeta potential of IPC based microparticles. The influence of 
HPBCD on the zeta potential of the microparticles was neg-
ligible. 
 The work of adhesion measurement was performed with 
the aim to evaluate the influence of the drug and polymers 
on the mucoadhesive properties of the prepared microparti-
cles. Work of adhesion values for obtained microparticles 
(MR1-MR6) was compared to the work of adhesion value 
for the corresponding polymer (HPMC, carbomer or IPC). 
The results of the in vitro mucoadhesion investigation are 
shown in Fig. 6. 
 Mucoadhesive properties of the drug-free HPMC based 
microparticles were less pronounced compared to the drug-
free carbomer and IPC based microparticles (Fig. 6). 
Risperidone incorporation into microparticles (MR1, MR3 
and MR5) reduced their mucoadhesive properties ~1.7 fold 
compared to the drug-free microparticles based on the same 
polymer. Incorporation of the drug in the form of cyclodex-
trin inclusion complex into microparticles (MR2, MR4 and 
MR6) caused no additional significant reduction of their mu-
coadhesive properties (p > 0.05). 
3.4. In Vitro Drug Release Studies 
 In vitro release studies were performed using the Franz-
diffusion cell. This model allowed slow hydratation of the 
samples in a humid environment, conditions designed to be 
similar to those encountered in the nasal cavity [11]. The 
release of the drug from the prepared solid products (R0, 
RHPBCD and microparticles MR1-MR6) included several 
steps, such as dissolution/release of the drug into the hydro-
dynamic layer on the membrane surface, followed by drug 
diffusion across the semipermeable membrane to the accep-
tor compartment of the Franz-diffusion cell. Both processes 
made a contribution to the overall release rate. The semiper-
meable membrane had a molecular weight cut-off value of 
600 Da, so risperidone could pass through freely. The ob-
tained drug release profiles are represented in Fig. 7. 
 To determine the drug release kinetics, experimental data 
were fitted to the zero-order and Higuchi kinetic models ac-
cording to equations (2) and (3). According to the correlation 
coefficient values (r
2
), the drug release from R0, RHPBCD and 
HPMC based microparticles (MR1 and MR2) could be de-
scribed by zero order kinetics, while the release of the drug 
from carbomer (MR3 and MR4) and IPC based microparti-
cles (MR5 and MR6) followed the Higuchi kinetic model 
(Fig. 7). For easier comparison of release profiles described 
by different kinetic models, dissolution efficiency was calcu-
lated according to equation (4). The dissolution efficiency is 
defined as the area under the dissolution curve up to certain 
time, expressed as the percentage of the area of the rectangle 
described by 100% dissolution in the same time. The values 
of risperidone release kinetic parameters for prepared solid 
products are shown in Table 3. 
 During the experiment, sink conditions in the donor com-
partment of the Franz-diffusion cell were not achieved, there-
fore dissolution efficiency in the case of spray-dried risperi-
done (R0) was low (Table 3). Incorporation of risperidone into 
the mucoadhesive microparticles had a significant influence 
on the kinetic parameters of drug release (Fig. 7A). The type 
of the mucoadhesive polymer used in the formulation affected 
the drug release rate. Risperidone incorporated into HPMC 
based microparticles (MR1) led to a 1.3 fold dissolution effi-
ciency increase compared to the spray-dried drug while the 
dissolution efficiency increase in the case of carbomer (MR3) 
and IPC based microparticles (MR5) was 5.9 and 6.3 fold, 
respectively. Inclusion complex formation (RHPBCD) signifi-
cantly enhanced the risperidone release rate (Fig. 7B), leading 
to a 3.2 fold dissolution efficiency increase compared to the 
spray-dried drug. HPBCD also increased risperidone dissolu-
tion efficiency for HPMC (MR2), carbomer (MR4) and IPC 
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(MR6) based microparticles compared to cyclodextrin-free 
microparticles prepared with the same polymer. 
Table 3. Kinetics Parameters of In Vitro Drug Release Stud-
ies: Zero Order (k0) and Higuchi (kH) Kinetics Con-
stants and Dissolution Efficiency (DE) of Various 
















R0 3.66 ± 0.04 -
a 7.96 ± 0.18 
RHPBCD 10.42 ± 0.23 -
a 25.07 ± 0.12b 
MR1 4.68 ± 0.03 -a 10.06 ± 0.06 
MR2 11.97 ± 0.19 -a 23.40 ± 0.28c 
MR3 -a 17.23 ± 0.43 33.53 ± 0.36 
MR4 -a 22.54 ± 0.49 47.14 ± 0.25d 
MR5 -a 22.77 ± 0.30 39.89 ± 0.32 
MR6 -a 30.05 ± 1.01 49.76 ± 0.26e 
a Correlation coefficients r2 < 0.95. 
Statistically significant differences: 
b P < 0.001 compared to spray-dried risperidone. 
c P < 0.001 compared to MR1. 
d P < 0.001 compared to MR3. 
e P < 0.001 compared to MR5. 
 
4. DISCUSSION 
4.1. Influence of HPMC and Carbomer on Risperidone 
Solubility and Inclusion Complex Formation in Solution 
 Addition of HPMC, a hydrophilic polymer, influenced 
risperidone solubility, indicating a drug-polymer interaction 
(Table 1). Heating and sonication of the samples increased 
risperidone solubility in water and promoted the drug-
polymer interaction. The interaction probably included for-
mation of the van der Waals and hydrogen bonds between 
the drug and polymer molecules, resulting in aggregate for-
mation [12]. Cooling of the samples led to the formation of a 
supersaturated drug solution, stabilised due to the drug-
polymer interaction. Therefore, risperidone solubility in 
HPMC solution was slightly higher than in water. 
 The presence of carbomer reduced only slightly risperi-
done solubility in water (Table 1). Different effects of 
HPMC and carbomer on the risperidone solubility could be 
associated with the different structure of polymers. The lin-
ear structure of HPMC allowed high flexibility of polymer 
chains, which could facilitate drug-polymer interaction. The 
cross-linked structure of the carbomer limited the mobility of 
the polymer chains. Therefore, the interaction of the drug 
with carbomer could be restrained for sterical reasons. Also, 
the carbomer is an anionic polymer, and its addition to sys-
tems increases the ionic strength of the media. High ionic 
strength could reduce risperidone solubility in a carbomer 
solution [13]. 
 Cyclodextrin inclusion complexes are known to interact 
with water-soluble polymers, resulting in formation of a ter-
nary complex consisting of the drug, cyclodextrin and poly-
mer [14]. The polymer coats the inclusion complex partially 
or totally, interacting with the drug and CD through hydro-
gen bonds. This interaction changes significantly the cyclo-
dextrin solubilising effect and the stability constant value of 
the inclusion complex. Solubility and stability constant data 
(Table 1) for the systems containing HPMC indicated that no 
formation of a ternary complex could be assumed. Higher 
risperidone solubility could be explained by simultaneous 
formation of the risperidone/HPBCD inclusion complex and 
drug-HPMC aggregates. Functional groups important for the 
interaction of the drug with HPMC were probably obscured 
by the inclusion complex formation, which reduced the af-
finity of HPMC for ternary complex formation. 
 The influence of carbomer on the risperidone/HPBCD 
inclusion complex formation in solution could be explained 
by the carbomer-cyclodextrin interaction. This interaction 
involved hydrogen bonds formation between the carboxyl 
groups of carbomer and hydroxyl groups of the cyclodextrin 
molecule [15]. The interaction with HPBCD is especially 
favoured, because HPBCD has a higher content of pendant 
hydroxyl groups, which are more accessible to hydrogen 
bonds establishment. This interaction could restrain the in-
clusion complex formation, probably for steric reasons. 
4.2. Solid State Studies of the Risperidone/HPBCD Inclu-
sion Complex 
 Based on the results of DSC experiments, a distinction 
can be made between the drug/cyclodextrin physical mixture 
and the inclusion complex in the solid state. The disappear-
ance of the risperidone fusion peak in the thermogram of the 
spray-dried complex indicated an amorphous drug state; and 
this state may be explained by inclusion complex formation 
since the spray-drying procedure had no significant influence 
on risperidone crystalline properties (Fig. 2). Due to complex 
formation, crystallisation of the drug during the spray-drying 
procedure was hampered, probably for steric reasons. The 
change of the drug fusion peak position and intensity in the 
risperidone/HPBCD physical mixture could be explained by 
thermally induced drug-cyclodextrin interaction during the 
experiment [16]. 
 Further evidence of inclusion complex formation was 
obtained by FTIR analysis. There are three known poly-
morphs of risperidone (A, B and E). In FTIR spectra of the 
crystalline drug and spray-dried risperidone, the vibration 
band at 1650.37 cm
-1
 appeared as a single peak, indicating 
the presence of the most stabile polymorph A in both sam-
ples [17]. Shift of the amide carbonyl absorption band in the 
spray-dried complex suggested the formation of hydrogen 
bonding between the amide carbonyl group of the drug and 
hydroxyl groups of the cyclodextrin molecule during the 
inclusion complex formation [18]. The inclusion complex 
formation restricted vibrational motions of an included drug 
moiety in the cyclodextrin cavity, resulting in decreased ab-
sorption band intensity. Therefore, the change of the amide 
carbonyl-stretching band position and intensity indirectly 
confirmed the inclusion complex formation. 
4.3. Preparation and Characterisation of Mucoadhesive 
Microparticles 
 Incorporation of risperidone in the form of inclusion 
complex into microparticles increased the drug loading (Ta-
ble 2). Due to the lipophilic nature of the drug, risperidone 
affinity for the interaction with the hydrophilic polymer was 
reduced, resulting in lower drug loading. The inclusion com-
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plex formation enhanced the hydrophilic nature of the drug 
and thereby facilitated its interaction with the hydrophilic 
polymer, and increased risperidone loading was observed. 
 To evaluate the internal structure modification, the pre-
pared microparticles were analysed by DSC (Fig. 4). Reduc-
tion in the onset temperature and risperidone fusion peak 
intensity in thermograms of HPMC based microparticles 
(MR1) indicated a partial loss of risperidone crystalline 
properties due to incorporation into the HPMC matrix, but 
the presence of the drug microcrystalline areas in the poly-
mer matrix could be still assumed. Disappearance of the 
risperidone fusion peak in carbomer and IPC based mi-
croparticles (MR3 and MR5, respectively) indicated forma-
tion of the drug molecular dispersion inside the polymer ma-
trix of the microparticles, probably due to the drug-polymer 
interaction. Risperidone possesses 3 tertiary amino groups in 
the molecule, and interaction between an amino group of the 
drug and an carboxyl group of the polymer may be assumed 
[19]. Absence of the risperidone fusion peak in thermograms 
of HPMC based microparticles containing HPBCD (MR2) 
might indicate that incorporation of the inclusion complex 
into the polymer matrix caused no degradation of the inclu-
sion complex. Disappearance of risperidone fusion peaks in 
thermograms of carbomer and IPC based microparticles con-
taining HPBCD (MR4 and MR6) may be attributed to the 
presence of the inclusion complex and/or the drug-polymer 
interaction. 
 Zeta potential measurements were carried out to investi-
gate surface characteristics of the prepared microparticles. 
Changes of the zeta potential might also point to interactions 
between the components of microparticles [20]. Chemical 
structure was the main parameter affecting the zeta potential 
of HPMC and carbomer drug-free microparticles. The inter-
polymer complex formation involved simultaneous estab-
lishment of a large number of intermacromolecular hydrogen 
bonds between carboxyl groups of the carbomer and hydro-
gen groups of HPMC [21]. This interaction reduced the 
number of charged carboxyl groups at the particle surface, 
thereby reducing negative zeta potential values of drug-free 
IPC microparticles. 
 The zeta potential reduction of the carbomer based mi-
croparticles containing the drug (MR3) revealed the electro-
static nature of the risperidone/carbomer interaction. A simi-
lar reduction of zeta potential was observed when risperi-
done was loaded in the form of an inclusion complex (MR4). 
The risperidone/HPBCD inclusion complex probably in-
volved partial insertion of the drug molecule into cyclodex-
trin cavity and one or two tertiary amide groups were still 
available for the interaction with the carboxyl groups of the 
carbomer. Due to this interaction, the number of charged 
carboxylic groups on the particle surface was reduced and 
therefore the zeta potential value was lower. Interpolymer 
complex formation occupied the carboxyl groups of the car-
bomer and sterically hampered its interaction with the drug 
molecules. Therefore, the presence of the drug, free or in the 
form of a cyclodextrin complex, had no significant influence 
on the zeta potential of IPC based microparticles (MR5 and 
MR6). 
 The type of polymer used for preparation of microparti-
cles determined their mucoadhesive properties. HPMC is a 
neutral polymer with a linear structure, and swelling of the 
polymer matrix occurred in contact with the mucosa, fol-
lowed by interpenetration of mucine and HPMC strands. A 
weak mechanical bond was thereby formed, which seems to 
be the main mechanism of the mucoadhesive bond formation 
[22]. Carbomer is a cross-linked polymer, and the large 
number of carboxyl groups contributed to fast swelling of 
the polymer matrix due to electrostatic repulsion forces be-
tween negatively charged segments of the polymer [23]. 
Pronounced swelling and the cross-linked structure of the 
carbomer contributed to the formation of a stabile mechanic 
mucoadhesive bond that could be further stabilised by hy-
drogen bonds [24]. IPC was formed by simultaneous estab-
lishment of a large number of hydrogen bonds between car-
bomer and HPMC strands (cooperative phenomena). The 
cooperativeness of this interaction led to the formation of a 
sufficiently stable ladder-type structure [21]. Interpenetration 
of mucine strands into this formed structure could lead to the 
formation of a strong mucoadhesive bond; hence, the muco-
adhesive properties of IPC and carbomer drug-free micropar-
ticles did not differ significantly (P>0.05). 
 Reduction in microparticles mucoadhesion after risperi-
done incorporation could be explained by lower polymer 
concentration in the matrix. Also, the presence of the drug 
molecule could prevent formation of electrostatic or hydro-
gen bonds, which are responsible for stabilisation of muco-
adhesive bonds [25]. The presence of cyclodextrin in the 
polymer matrix did not significantly affect the mucoadhesive 
properties of microparticles. This may be explained in part 
by the results of zeta potential measurements, which indi-
cated that the polymer was the main component on the sur-
face of microparticles. Also, it has been demonstrated that 
HPBCD has a positive effect on the swelling properties of 
HPMC and carbomer based matrices [26]. The presence of a 
readily soluble, amorphous inclusion complex in the polymer 
matrix could promote hydration of the matrix, acting as a 
channelling or wicking agent. Thus, the polymer matrix con-
taining HPBCD could swell more rapidly compared to the 
matrix without cyclodextrin. Swelling of the matrix may lead 
to greater mobility of the polymer chain segments, which 
could increase the availability of polymer chains for the in-
teraction with mucine and the mucoadhesive bond formation. 
4.4. In Vitro Drug Release Studies 
 In vitro release studies were intended to investigate the 
influence of inclusion complex formation and incorporation 
of the drug into mucoadhesive microparticles upon the 
risperidone release properties under the conditions designed 
to be similar to those of the nasal cavity. 
 The main parameter affecting risperidone release in vitro 
was the drug solubility. Due to low risperidone solubility, 
only limited amounts of the drug were available for diffusion 
in the acceptor phase, leading to low values of the kinetic 
parameters (Table 3). Incorporation of the drug into mi-
croparticles enhanced the drug dissolution rate. The presence 
of the hydrophilic polymer facilitated to some extent the 
wetting of drug particles, providing a lower energy pathway 
for drug dissolution. The effect of HPMC on the drug disso-
lution rate was inferior compared to that of carbomer and 
IPC (Table 3). This could be connected with the presence of 
the drug microcrystalline regions in the HPMC microparti-
cles (MR1), as shown by DSC studies. On the other hand, in 
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carbomer and IPC microparticles (MR3 and MR5, respec-
tively), the drug was molecularly dispersed in the polymer 
matrix due to interactions with the polymer. This could lead 
to faster risperidone release. Also, the ionic strength of the 
dissolution medium has a significant impact on the swelling 
and erosion of HPMC matrices and thereby on drug release 
[27]. During the experiment, microparticles were in contact 
with the dissolution medium, and swelling of the polymer 
matrix occurred, leading to the formation of a gel layer 
around the dry core. Drug diffusion in the gel layer and ero-
sion of the polymer matrix were the main mechanisms con-
trolling the drug release [28]. Uptake of the dissolution me-
dium into HPMC microparticles (MR1) was followed by 
partial ionisation of risperidone molecules inside the poly-
mer matrix. Charged drug molecules may compete for avail-
able water of hydration with HPMC chains, leading to 
slower swelling and erosion of the microparticles. This 
might affect the drug release. Therefore, a lower concentra-
tion of the drug was available for diffusion across the 
semipermeable membrane, leading to lower drug concentra-
tion in the acceptor phase. Uptake of the dissolution media 
into MR3 and MR5 microparticles caused ionisation of the 
polymer carboxyl groups, leading to the formation of an 
acidic microenvironment [29]. This could increase drug 
solubility in the swollen gel layer and thereby facilitate drug 
release. 
 Inclusion complex formation significantly enhanced the 
risperidone (RHPBCD) release rate and increased the dissolu-
tion efficiency (Table 3). Though the complex could not 
penetrate the membrane, the drug in the complex was in 
rapid dynamic equilibrium with the “free” drug, thus con-
tinuously supplying risperidone molecules to the membrane 
in a diffusible form. Cyclodextrin complexation increased 
the drug concentration gradient over the membrane, which 
led to higher drug concentrations in the acceptor compart-
ment. 
 Incorporation of risperidone/HPBCD into microparticles 
additionally increased the drug release rate, leading to higher 
dissolution efficiency compared to cyclodextrin-free mi-
croparticles (Table 3). The inclusion complex formation en-
hanced risperidone solubility in the swollen gel layer of the 
microparticles and thereby increased the concentration of 
diffusible species within the matrix. This contributed to the 
overall release rate. Also, the presence of HPBCD in the 
microparticles could enhance drug release by acting as a 
channelling or wicking agent [30]. This increased the diffu-
sion of the dissolution medium into microparticles and 
thereby promoted their swelling and erosion. Enhanced ero-
sion of the microparticles containing HPBCD could also 
contribute to faster drug release, leading to higher dissolu-
tion efficiency. 
 The presence of carbomer, free or as interpolymer com-
plex, seems to be essential for the kinetic type of drug re-
lease from the microparticles, irrespective of HPBCD pres-
ence (Fig. 7). According to the r
2
 value, drug release from 
those microparticles (MR3-MR6) followed the Higuchi 
square root of time equation. Fast swelling of MR3-MR6 
microparticles and the acidic microenvironment of the 
formed gel layer [23] may increase risperidone solubility. 
This contributed to fast initial drug release ("burst effect"). 
During the experiment, the drug concentration in the mi-
croparticles decreased causing a decrease of the overall drug 
release rate. In the case of HPMC based microparticles 
(MR1-MR2), drug release occurred at a constant rate during 
the experiment, showing a better fit to the zero-order kinetic 
model (Table 3). This behaviour may be attributed to slower 






















Fig. (7). In vitro release of risperidone from prepared microparticles 
without (A) and with HPBCD (B). 
 The influence of HPBCD on risperidone release from 
mucoadhesive microparticles was studied in order to over-
come formulation problems associated with designing a con-
trolled release system intended for nasal administration of 
low solubility drugs. It has been demonstrated that HPBCD 
can enhance risperidone release with a minimal influence on 
mucoadhesive properties of the microparticles. The results 
suggest that this effect can be attributed to the ability of 
HPBCD to form an inclusion complex with risperidone, re-
sulting in increased drug solubility. Also, the risperi-
done/carbomer interaction demonstrated by the DCS analysis 
and zeta potential measurements additionally enhanced the 
drug release rate. Polymeric matrices containing the muco-
adhesive components and cyclodextrin inclusion complex 
may be used as a non-invasive alternative to oral drug ad-
ministration, providing sustained drug release in vitro. 
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ABBREVIATIONS 
DE = Dissolution efficiency 
DSC = Differential scanning calorimetry 
FTIR = Fourier transform infrared spectroscopy 
HPBCD = Hydroxypropyl-beta-cyclodextrin 
HPMC = Hydroxypropylmethyl cellulose 
IPC = HPMC/carbomer interpolymer complex 
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